Pharma watchers know that high-profile price hikes have galvanized public backing for cost-fighting measures–and that November’s election could ratchet up the pressure even more. Now, PhRMA’s raising hundreds of millions to fund a counteroffensive.
The lobby group is increasing dues by 50%, a move that’ll enable it to bring in $300 million a year to spend on ads defending its member companies, Politico reports. That’s as discussion continues to swirl around now-notorious price hikes by PhRMA nonmembers Mylan Pharmaceuticals and Valeant Pharmaceuticals.
Just last week, PhRMA member company Ariad was also pulled into the spotlight by frequent industry critics Sen. Bernie Sanders and Rep. Elijah Cummings for “staggering” price increases on its leukemia drug Iclusig. The watchdog lawmakers are asking the Cambridge, MA-based drugmaker for documents on Iclusig revenues, expenses, sales contracts and more.
Ariad said it “recognizes the high cost of innovative oncology drugs and believes in the importance and efficacy of its products.” It’s spent $1.3 billion on R&D so far and isn’t making a profit, the statement said.
Amid the nationwide conversation, faith-based investor organization ICCR has its own pricing campaign going. The group has called for more pricing transparency through shareholder resolutions at 11 leading U.S. pharma companies and through investor letters to six foreign pharmas.
And in California, pharma companies are working feverishly to defeat Proposition 61. The ballot proposal, endorsed by Sanders, would require the state to buy prescription drugs at prices no higher than those charged by the U.S. Department of Veterans Affairs. Some industry leaders fear the tactic could spread elsewhere if passed in the nation’s most populous state.
PhRMA’s lobbying and advertising efforts run parallel to those from biotech trade group BIO, which said in June it was saddling up to reshape the conversation around drug pricing. In remarks to a conference audience, BIO President Jim Greenwood said the industry was tired of playing “scapegoat.” The group set up a “rapid response shop in Washington to beat back misinformation,” Greenwood told the crowd, and armed its members with fact sheets to press the industry’s case.
Despite all the scrambling and criticism, and proposals from presidential front-runner Hillary Clinton, industry analysts have predicted that meaningful action won’t happen until 2017, and only then as part of an Affordable Care Act overhaul.
Throughout this year’s campaign, each presidential candidate has weighed in on methods to rein in high drug costs. Democratic nominee Clinton rolled out a slate of proposals last year, including Medicare price negotiation and drug reimportation. More recently, she said that, if elected, she’d task a panel of governmental agency representatives, advised by other stakeholders, to scour for “outlier” price hikes and then impose punishment.
Republican nominee Donald Trump has backed drug reimportation, among a variety of broader healthcare proposals. At one point, Trump crossed party lines to endorse Medicare price negotiations, but his healthcare plan didn’t include that provision.
PhRMA decided to raise dues this summer, Politico previously reported. The trade group wouldn’t comment on its budget to FiercePharma.
By Eric Sagonowsky
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
